Trial · NCT07511049
Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study
NCT07511049, Phase 2, Recruiting, National Institute of Neurological Disorders and Stroke (NINDS)
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study. Trials, record NCT07511049. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07511049
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Intravenous Brincidofovir as an Antiviral for Treatment of Progressive Multifocal Leukoencephalopathy: A Pilot Study
- NCT number
- NCT07511049
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 24 participants, estimated
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- Conditions
- Progressive Multifocal Leukoencephalopathy
- Interventions
- Brincidofovir
- First posted
- 2026-04-06
- Last updated
- 2026-07-22
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of treatment-related adverse events (AEs) of Grade 3 severity or higher as determined by Common Terminology Criteria for Adverse Events (CTCAE) | Over duration of trial participation | |
| Secondary | Incidence of treatment-related AEs, regardless of severity | over duration of trial | |
| Secondary | Change from baseline in JCPyV load in CSF upon completion of each Treatment Block | at end of each treatment block | |
| Secondary | Proportion of patients with 0.25log decline or greater in JCPyV load in CSF upon completion of each Treatment Block | at end of each treatment block | |
| Secondary | Time to increase in JCPyV load in CSF during monitoring phase upon treatment completion | over duration of trial participation | |
| Secondary | Number of Treatment Blocks and duration of treatment phase | dependent on duration of participation: 1 month - 3 months | |
| Secondary | Number of patients meeting Treatment Failure Criteria | At end of each treatment block | |
| Secondary | Change from baseline in performance and standardized disability rating scales at 6, 9 and 12 months | 6, 9 and 12 months | |
| Secondary | Change from baseline in PML lesion burden by brain MRI at 3, 6 9 and 12 months | 3, 6, 9 and 12 months | |
| Secondary | Survival at 3, 6, 9 and 12 months | 3, 6, 9 and 12 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07511049
GET https://conductscience.org/api/trials/v1/NCT07511049/registered